CellSeed Inc. (JP:7776)
:7776
7776 Stock Chart & Stats
¥259.00
-¥7.00(-1.73%)
At close: 4:00 PM EST
¥259.00
-¥7.00(-1.73%)
Day’s Range― - ―
52-Week Range¥231.00 - ¥668.00
Previous CloseN/A
Volume900.50K
Average Volume (3M)621.90K
Market Cap
¥11.20B
Enterprise Value¥7.80B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.30
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.31
Shares Outstanding38,873,920
10 Day Avg. Volume981,780
30 Day Avg. Volume621,903
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.08
Price to Sales (P/S)107.39
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Regenerative Tech & ManufacturingCellSeed’s specialization in cell sheet engineering and in-house development and manufacturing creates durable product and service capabilities. Vertical expertise and manufacturing know-how raise barriers to entry, support long-term partnerships, and position the firm to capture value as therapies progress toward commercialization.
Healthy Gross MarginsSustained gross margins in the 48–69% range indicate strong unit economics at the product level. If revenue stabilizes or scales, these margins can drive operating leverage and meaningful improvements in profitability without requiring proportional increases in input costs.
Low Financial LeverageModest debt levels provide financial flexibility to fund R&D, regulatory work, or bridge financing rounds without heavy interest burdens. Low leverage reduces near-term solvency risk and preserves capacity to raise capital on workable terms despite current losses.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow demonstrates the business cannot self-fund operations. Over months, this increases reliance on external financing, raising dilution and execution risk. Continued burn constrains investment in commercialization and prolongs the path to sustainable operations.
Sharp Revenue DeteriorationA large year-over-year revenue decline signals weakening commercial traction or disrupted sales execution. Structural revenue shrinkage undermines scalability, stresses fixed-cost absorption, and complicates forecasting and investment choices needed to reach a break-even operating model.
Very Large Operating Losses & Equity ErosionExtremely negative margins and falling shareholder equity indicate losses are eroding capital and returns. This trend elevates funding and dilution risk, weakens stakeholder confidence, and may force strategic trade-offs between financing, R&D pace, and commercialization priorities over the medium term.
CellSeed Inc. News
7776 FAQ
What was CellSeed Inc.’s price range in the past 12 months?
CellSeed Inc. lowest stock price was ¥231.00 and its highest was ¥668.00 in the past 12 months.
What is CellSeed Inc.’s market cap?
CellSeed Inc.’s market cap is ¥11.20B.
When is CellSeed Inc.’s upcoming earnings report date?
CellSeed Inc.’s upcoming earnings report date is May 13, 2026 which is in 37 days.
How were CellSeed Inc.’s earnings last quarter?
CellSeed Inc. released its earnings results on Feb 13, 2026. The company reported -¥7.31 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.31.
Is CellSeed Inc. overvalued?
According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued.
Does CellSeed Inc. pay dividends?
CellSeed Inc. does not currently pay dividends.
What is CellSeed Inc.’s EPS estimate?
CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSeed Inc. have?
CellSeed Inc. has 38,873,920 shares outstanding.
What happened to CellSeed Inc.’s price movement after its last earnings report?
CellSeed Inc. reported an EPS of -¥7.31 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.305%.
Which hedge fund is a major shareholder of CellSeed Inc.?
Currently, no hedge funds are holding shares in JP:7776
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSeed Inc.
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
StemCell Institute
―
Japan Tissue Engineering Co., Ltd.
―